Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia

Nature Communications

Volumn 5, Issue , 2014, Pages

  Mar, Brenton G ^a,b   Bullinger, Lars B ^c   McLean, Kathleen M ^a   Grauman, Peter V ^d   Harris, Marian H ^b   Stevenson, Kristen ^a   Neuberg, Donna S ^a   Sinha, Amit U ^e   Sallan, Stephen E ^a,b   Silverman, Lewis B ^a,b   Kung, Andrew L ^f   Lo Nigro, Luca ^g   Ebert, Benjamin L ^d   Armstrong, Scott A ^e  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF ULM   (Germany)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f NewYork Presbyterian Hospital   (United States)

^g Azienda Policlinico   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MSH6; HISTONE LYSINE METHYLTRANSFERASE; PRIMER DNA; SET2 PROTEIN, HUMAN;

CANCER; DISEASE TREATMENT; GENETIC ANALYSIS; MUTATION;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CHILDHOOD CANCER; COHORT ANALYSIS; EPIGENETICS; FRAMESHIFT MUTATION; GENE MUTATION; GENE SEQUENCE; HUMAN; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; NONSENSE MUTATION; SOMATIC MUTATION; DNA SEQUENCE; EXON; GENETIC EPIGENESIS; GENETICS; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENT DISEASE; TREATMENT FAILURE;

BASE SEQUENCE; DNA PRIMERS; EPIGENESIS, GENETIC; EXONS; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; SEQUENCE ANALYSIS, DNA; TREATMENT FAILURE;

EID: 84907418637     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms4469     Document Type: Article

References (17)

1. Mullighan, C. G. et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322, 1377-1380 (2008).
2. Zhang, J. et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481, 157-163 (2012).
3. Holmfeldt, L. et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat. Genet. 45, 242-252 (2013).
4. Mullighan, C. G. et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 471, 235-239 (2011).
5. De Keersmaecker, K. et al. Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. Nat. Genet. 45, 186-190 (2013).
6. Mar, B. et al. Sequencing histone-modifying enzymes identifies UTX mutations in acute lymphoblastic leukemia. Leukemia. 26, 1881-1883 (2012).
7. Dalgliesh, G. et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463, 360-363 (2010).
8. Tzoneva, G. et al. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat. Med. 19, 368-371 (2013).
9. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. New Engl. J. Med. 368, 2059-2074 (2013).
10. Li, F. et al. The histone mark H3K36me3 regulates human dna mismatch repair through its interaction with MutSalpha. Cell 153, 590-600 (2013).
11. Diouf, B. et al. Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. Nat. Med. 17, 1298-1303 (2011).
12. Wagner, E. & Carpenter, P. Understanding the language of Lys36 methylation at histone H3. Nat Rev Mol Cell Biol 13, 115-126 (2012).
13. Jaffe, J. D. et al. Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. Nat. Genet. 45, 1386-1391 (2013).
14. Oyer, J. et al. Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies. Leukemia. 28, 198-201 (2013).
15. Meyer, J.A. et al. Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet 45, 290-294 (2013).
16. Spiegel, S., Milstien, S. & Grant, S. Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene 31, 537-551 (2012).
17. Daigle, S. et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20, 53-65 (2011).